ExodusPoint Capital Management’s Anixa Biosciences ANIX Stock Holding History

ExodusPoint Capital Management’s Portfolio ANIX Stock Details ANIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-93,931	Closed	-$293K	–	1534
2025 Q4	$293K	Buy	+93,931	New	+$385K	﹤0.01%	1317
2022 Q1	–	Sell	-10,029	Closed	-$30K	–	2162
2021 Q4	$30K	Buy	+10,029	New	+$40.5K	﹤0.01%	2068

Other funds holding ANIX

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

LNWTC

Laird Norton Wetherby Trust Company Seattle, Washington $4.58B AUM 30.77% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

DADC

D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

ExodusPoint Capital Management's ANIX Position: Q1 2026 in Review

ExodusPoint Capital Management sold out of Anixa Biosciences (ANIX) in Q1 2026, closing a stake of 93,931 shares — an estimated $293K sold.

ExodusPoint Capital Management first reported a position in ANIX in Q4 2021 and held it in 2 quarters. The position peaked at $293K in Q4 2025. 60 funds tracked by Wall St. Rank hold ANIX as of Q1 2026.

ExodusPoint Capital Management reported no remaining Anixa Biosciences position as of Q1 2026 after selling out during the quarter.
ExodusPoint Capital Management sold 93,931 Anixa Biosciences shares in Q1 2026, an estimated $293K.
ExodusPoint Capital Management first reported a position in Anixa Biosciences in Q4 2021 and held it in 2 quarters.
ExodusPoint Capital Management's Anixa Biosciences position peaked at $293K in Q4 2025.
60 funds tracked by Wall St. Rank held Anixa Biosciences as of Q1 2026.

Based on ExodusPoint Capital Management's 13F filing for Q1 2026, filed 14 May 2026.